Trial Profile
A randomized Phase II study comparing SOX+B-mab with SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with KRAS wild type
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2023
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Bevacizumab; Cetuximab
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms SOX+BC
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium
- 14 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Nov 2011 New trial record